PIK3CA mutation detection by circulating tumor cell sequencing guides the effective PI3K inhibitor treatment of a patient with hormone receptor-positive breast cancer transformed into triple-negative breast cancer: A case report
Jing Zhang, Jing Pei, Guangxu Hao, Yao Meng, Fei Li, Heng Xu, Hong Liu · 2026
Read PIK3CA mutation detection by circulating tumor cell sequencing guides the effective PI3K inhibitor treatment of a patient with hormone receptor-positive breast cancer transformed into triple-negative breast cancer: A case report by Jing Zhang, Jing Pei, Guangxu Hao, Yao Meng, Fei Li, Heng Xu, Hong Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13183117.txt.
Description
Jing Zhang and co-authors report a breast cancer that changed its type under treatment, and how a blood test found its new weakness. Their case report appeared in 2026. The patient, a 51-year-old woman, began with hormone-sensitive cancer in 2021. Hormone therapy and a cell-cycle drug failed, and the tumor returned as triple-negative, the hardest form. Sequencing cancer cells caught from her blood found a PIK3CA mutation, a growth-switch flaw.
A drug blocking that pathway then controlled the disease for seven months, with side effects she could tolerate. The authors say circulating tumor cells can reveal a cancer's new drivers when a fresh tissue biopsy is hard, and can point treatment after standard options run out.
Catalog record
| CREATOR | Jing Zhang, Jing Pei, Guangxu Hao, Yao Meng, Fei Li, Heng Xu, Hong Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |